ASCO Highlight Breast Cancer
Mediahuset invite you to our ASCO Highlights webinar, summarizing the most important breast cancer topics from ASCO 2022!
We hope that you are able to join us online.The live participants can of course ask questions and comment in the Q&A section. This webcast is free of charge thanks to our sponsors. Register via the button to the right.
Time: 7.00pm-8.40pm (CET)
Renske Altena, MD PhD senior consultant oncology and internal medicine Karolinska University Hospital
Jonas Bergh, professor and senior consultant oncology Karolinska University Hospital and Karolinska Institutet
Javier Cortes, Professor
Marleen Kok, Associate professor
Matteo Lambertini, Associate professor
7.00-7.05 Welcome, Renske Altena
7.05-7.25 Triple negative breast cancer and immunotherapy for breast cancer, Marleen Kok
7.35-7.55 HER2-positive breast cancer, Javier Cortes
8.05-8.25 Luminal tumors and fertility issues, Matteo Lambertini
8.35-8.40 Concluding remarks Jonas Bergh
Dr Javier Cortes
Head of breast cancer and gynecological cancers at Hospital Universitario Ramón y Cajal in Madrid, Spain, as well as Clinical Investigator in the breast cancer research program at Vall d’Hebron Institute of Oncology in Barcelona, Spain.
He is one of the European leaders in the field of HER2+ breast cancer, and has led fundamental trials that resulted in the approval of pertuzumab, eribulin and everolimus for metastatic breast cancer. He continues to actively participate in national and international clinical investigations to develop molecularly targeted therapies, such as CDK 4/6 inhibitors, and immunotherapies.
Dr Cortés is on the Scientific Committee of ESMO and is an active member of ASCO and the Spanish Society of Medical Oncology.
Dr Marleen Kok
After finishing Medical School (2004) including an undergraduate research training on neuroblastoma genetics at the prestigious University of Pennsylvania (Philadelphia, USA), Marleen Kok performed her Ph.D. research from 2004-2009 at The Netherlands Cancer Institute. Working in the labs of Laura van 't Veer (currently at UCSF) and Sabine Linn (NKI, Amsterdam), she tested the predictive value of gene signatures as well as modifications of the Estrogen Receptor to predict tamoxifen resistance. This training by true experts in the field of breast cancer biomarkers forms a solid basis to pursue her career in translational breast cancer research.
After her residency/fellowship (2009-2015) in Internal Medicine/Medical Oncology she worked as postdoctoral fellow (2015-2016) of the Dutch Cancer Society at John Hopkins University (Baltimore, USA) in the labs of Leisha Emens and Drew Pardoll. We showed that intratumoral STING (Stimulator of Interferon Genes) agonists can potently prime tumor antigen-specific CD8+ T cell responses.
In 2016 Marleen Kok returned to the NKI to work as Medical Oncologist and translational research fellow in the lab of Ton Schumacher (2016-2018), who is world-leading in the field of T cell biology. She is the lead PI of several innovative investigator-initiated breast immunotherapy trials evaluating the efficacy of PD1-blockade with (low dose) chemotherapy and since 2019 she is Group Leader at the NKI with a focus on translational breast cancer immunology.
Dr Matteo Lambertini
Assistant professor and consultant in medical oncology at the IRCCS Ospedale Policlinico San Martino – University of Genova in Genova (Italy).
He is mainly focused on the care of breast cancer patients and is deeply involved in breast cancer research.
Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they must face after diagnosis.
During his medical oncology training, he had the opportunity to work and collaborate with several national and international leading experts in the field; these experiences have played a crucial role to deepen his skills in the management of breast cancer in young women.
Thanks to the support of the European Society for Medical Oncology (ESMO), in 2018 he completed his PhD at the Université Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy-related Issues in Young Breast Cancer Patients”.
With this work, he has contributed to the understanding of many controversial aspects related to the management of breast cancer in young women specifically focusing on fertility preservation and the possibility to have a pregnancy following treatment completion, with the goal to further improve the care and quality of life of these young women.
Prof Lambertini is member of the European Society for Medical Oncology (ESMO), member of the ESMO Young Oncologists Committee (YOC) and member and first author of the author group of the ESMO guidelines on Fertility Preservation in Cancer Patients.
He is member of the European Society of Human Reproduction and Embryology (ESHRE) and the Italian Association of Medical Oncology (AIOM).
He has authored several publications in peer-reviewed journals and book chapters in the field of breast cancer in young women. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy (Lambertini M, et al. JAMA 2015 & Lambertini M, et al. Ann Oncol 2015 & Lambertini M, et al. Eur J Cancer 2017 & Lambertini M, et al. J Clin Oncol 2018), the safety of having a pregnancy in women with prior history of breast cancer (Lambertini M, et al. JNCI 2018 & Lambertini M, et al. Cancer 2019) and the fertility and pregnancy-related issues in BRCA-mutated breast cancer patients (Lambertini M, et al. Ann Oncol 2018 & Lambertini M, et al. RBO 2019 & Lambertini M, et al. Front Oncol 2019 & Lambertini M, et al. J Clin Oncol 2020).
The final content of the program will be decided exclusively by the moderators/speakers. The sponsors will not be able to influence the program.